International Journal of Medical Science and Pharmaceutical Research

Population pharmacokinetic/pharmacodynamic (PK/PD) modeling now sits at the center of model-informed drug development (MIDD), shaping dose selection, labeling language, and regulatory submissions across therapeutic areas. Less attention goes to the statistical and clinical programmers who build the analysis-ready datasets. These models depend on a role distinct from the pharmacometrician who fits the model itself. This article proposes a four-domain framework for describing that contribution: noncompartmental analysis (NCA) dataset construction and quality control;population PK datasetand diagnostic-output support; exposure-response and dose-selection analysis support; and specialized regulatory analysesspanning drug-drug interaction, bioequivalence, and pediatric extrapolation studies. Drawing on FDA and CDISC guidance, implementation standards, and pharmacometrics practice literature, the synthesis characterizes the technical demands, regulatory touchpoints, and quality-control conventions specific to each domain. Programmer contribution turns out to escalate unevenly rather than proportionally across domains: dataset-construction choices especially around below-limit-of-quantification handling and covariate dataset structure carry direct downstream weight on model validity and labeling claims, and this weight increases sharply once analyses move into specialized regulatory territory. With FDA’s PDUFA VII commitments extending MIDD infrastructure through fiscal years 2023 to 2027, the framework gives a vocabulary for a programming specialization that current workforce literature treats as undersupplied relative to demand,with direct bearingon training pathways and staffing models for regulatory-facing quantitative pharmacology teams.

Population pharmacokinetics; Model-informed drug development; Statistical programming; Noncompartmental analysis; CDISC ADaM; Regulatory submissions.

1. Food and Drug Administration. Population Pharmacokinetics: Guidance for Industry. SilverSpring (MD): FDA; 2022. Available from: https://www.fda.gov/media/128793/download
2. Federal Register. Population Pharmacokinetics; Guidance for Industry; Availability. 87 Fed Reg 6435 (Feb 4, 2022). Available from: https://www.federalregister.gov/documents/2022/02/04/2022-02355/population-pharmacokinetics-guid ance-for-industry-availability
3. Food and Drug Administration. Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens. Silver Spring (MD): FDA. Available from: https://www.fda.gov/media/151745/download
4. Wu G, et al. A Retrospective Evaluation of Allometry, Population Pharmacokinetics, and Physiologically-Based Pharmacokinetics for Pediatric DosingUsing Clearance as a Surrogate. CPT Pharmacometrics Syst Pharmacol. 2019. Available from: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.12385
5. Liu T, GhafooriP, Gobburu JVS. Allometry Is a Reasonable Choice in Pediatric Drug Development. J Clin Pharmacol. 2017;57(4):469-475. Available from: https://accp1.onlinelibrary.wiley.com/doi/abs/10.1002/jcph.831
6. Mahmood I. An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children:Towards Decision Tables.Expert Opin Drug Metab Toxicol.2021;18(2). Available from: https://www.tandfonline.com/doi/abs/10.1080/17425255.2021.2027907
7. Food and Drug Administration. Clinical Drug Interaction Studies Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions: Guidancefor Industry. FederalRegister (Jan 23, 2020). Available from: https://www.federalregister.gov/documents/2020/01/23/2020-01064/clinical-drug-interaction-studies-cy tochrome-p450-enzyme--and-transporter-mediated-drug-interactions
8. Sudsakorn S, Bahadduri P, et al. 2020 FDA Drug-Drug Interaction Guidance: Comparison Analysisand Action Plan by Pharmaceutical Industrial Scientists. ResearchGate. Available from: https://www.researchgate.net/publication/342341673
9. Food and Drug Administration. Statistical Approaches to Establishing Bioequivalence: Guidance for Industry. Silver Spring (MD): FDA. Available from: https://www.fda.gov/media/167453/download
10. Food and Drug Administration. Statistical Procedures for Bioequivalence StudiesUsing a Standard Two-Treatment Crossover Design: Guidance for Industry. Silver Spring (MD): FDA.
11. Statistics in Biopharmaceutical Research.Methods for Non-Compartmental Pharmacokinetic Analysis With Observations Below the Limit of Quantification. 2019. Available from: https://www.tandfonline.com/doi/full/10.1080/19466315.2019.1701546
12. CDISC. ADaM popPK Implementation Guide v1.0. ClinicalData Interchange StandardsConsortium. Available from: https://www.cdisc.org/adam-poppk-implementation-guide-v1-0
13. International Society of Pharmacometrics / Higher Logic. Basic Data Structure for ADaM PopPK Implementation Guide Version 1.0. Available from: https://higherlogicdownload.s3.amazonaws.com/ISOP/ab9a664e-5553-438f-b035-82b1e69e5009/Uplo adedImages/Documents/BDS_for_ADaM_PopPK_Implementation_Guide_v1_0_0.pdf
14. Kapitanov E, et al. Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development. Clin Pharmacol Ther. 2026. Available from: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.70191
15. Federal Register.Prescription Drug User Fee Act of 2023 VII MeetingsProgram for Model-Informed Drug Development Approaches. (Jan 11, 2023). Available from: https://www.federalregister.gov/documents/2023/01/11/2023-00389/
16. PHUSE / Wiki.cdisc.org. Implementation of CDISC ADaM in the Pharmacokinetics Department. Available from: https://wiki.cdisc.org/download/attachments/55972337/4.Implementation%20of%20CDISC%20ADaM%20in%20PK%20dpt.pdf
17. Jamsen KM, et al. A Regression Approach to Visual Predictive Checks for Population Pharmacometric Models. CPT Pharmacometrics Syst Pharmacol. 2018. Available from: https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/psp4.12319
18. Food and Drug Administration. Exposure-Response Relationships Study Design, Data Analysis, and Regulatory Applications: Guidance for Industry. Silver Spring (MD): FDA. Available from: https://www.fda.gov/media/71277/download
19. Food and Drug Administration. Guidance for Industry:End-of-Phase 2A Meetings.Silver Spring (MD): FDA. Available from: https://www.fda.gov/media/72211/download
20. UDSpace / PMC. Model-Informed Drug Development: Addressing the Critical Need for Trainingin the Promising New Field. 2026. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC13048755/
21. Applied ClinicalTrials Online. PhaseIII Trial Failures: Costly, But Preventable. Available from: https://www.appliedclinicaltrialsonline.com/view/phase-iii-trial-failures-costly-preventable